Electroencephalography

American Aires Expanding Product Use Case to Include eSports & Gaming

Retrieved on: 
Thursday, February 10, 2022
EMF, EMR, CSE, Memory, Solution, VR, Company, Anxiety, Marketing, Military personnel, Vision, Headache, Technology, CA, Electronic oscillator, Publication, Brain, Central nervous system, Human, CEO, Movement, Electromagnetic radiation, OTCQB, Electroencephalography, Database, WIFI, Formula One, Computer, Occupational burnout, Esports, Video game, Mobile phone, Medical imaging, Metaverse, LATAM Colombia

Symptoms include reduced focus, memory, reaction speed, concentration, mood, and energy levels, as along with chronic headaches, difficulty sleeping, and anxiety.

Key Points: 
  • Symptoms include reduced focus, memory, reaction speed, concentration, mood, and energy levels, as along with chronic headaches, difficulty sleeping, and anxiety.
  • The military air defense operators experienced a measurable decline of these performance functions which led to the inception of Aires' core technology.
  • Using electroencephalography ("EEG"), Dr. Dogris mapped real-time brain activity while using gaming technology and then ran the same experiment with the addition of the Aires product.
  • American Aires Inc. is Canadian-based nanotechnology company which has developed proprietary silicon-based microprocessors that reduce the harmful effects of electromagnetic radiation (EMR).

The iDentalwig™: New Dental Sensor™ System to Monitor the Body 24/7

Retrieved on: 
Tuesday, February 8, 2022
Heart failure, Apple Watch, News, Dentistry, Patent, Pfizer, Philosophy, Time, Muscle, Research, Tooth, Pulmonary artery, Body, Profile, Alzheimer's disease, Apple, Heart, Efficiency, FDA, Technology, Knowledge, EEG, Dentures, Electricity, Brain, Blood, Blood pressure, Learning, Death, Stroke, Crown, Swallow, Electroencephalography, Parkinson's disease, Physician, CAGR, Smartphone, Mouth, Breast implant, MRI, Running, Medical imaging, Mobile phone, Medical device, Electric battery, Pharmaceutical industry

The iDentalWig is a wearable dental device that looks and feels a lot like our Dental Wig alternative to dental implants but stands out by having the ability to monitor the human body.

Key Points: 
  • The iDentalWig is a wearable dental device that looks and feels a lot like our Dental Wig alternative to dental implants but stands out by having the ability to monitor the human body.
  • Of course, there are machines and technology that monitor the body.
  • In fact, we believe that we can do something better in the form of the iDentalWig to monitor body functionality.
  • This New Dental Sensor System to Monitor the Body breakthrough technology has multiple applications.

Children’s Hospital Los Angeles Awarded $8.3 Million to Study Long-Term Effects of COVID in Children

Retrieved on: 
Wednesday, January 26, 2022
Health, Consumer, Infectious Diseases, Hospitals, Children, Baby, Maternity, COVID-19, Heart rate, Name, Children's Hospital Los Angeles, Lung, Keck School of Medicine of USC, Blog, Disorder, USC, National, Parent, U.S. News & World Report, Headache, Patient, Hospital, Principal, Magnetic resonance imaging, Population, COVID, Hope, Medicine, Kidney, Child, Brain, Twitter, Multimedia, News, Research, Risk, Adult, Friends, Program, Instagram, Pregnancy, Heart, Electrocardiography, LinkedIn, Infection, NIH, CHLA, PASC, Severe acute respiratory syndrome coronavirus 2, Doctor of Philosophy, Physician, Liver, Caregiver, Sleep, Fatigue, MIS-C, YouTube, Electroencephalography, Pharmaceutical industry, Facebook, MD

Childrens Hospital Los Angeles is one of the few hospitals in California with a program dedicated to long COVID recovery care in children and young adults.

Key Points: 
  • Childrens Hospital Los Angeles is one of the few hospitals in California with a program dedicated to long COVID recovery care in children and young adults.
  • The study also will focus on two other post-COVID/PASC conditions Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID vaccine-associated myocarditis .
  • Founded in 1901, Children's Hospital Los Angeles is the highest-ranked hospital in California and fifth in the nation on the prestigious U.S. News & World Report Honor Roll of Best Childrens Hospitals.
  • The hospital also operates the largest pediatric residency training program at a freestanding childrens hospital in the Western United States.

Global Earphones and Headphones Market Trajectory & Analytics Report 2022: The Age of Hearables, Innovations, and World Brands - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Technology, Consumer Electronics, Atmos, Dolby Atmos, CAGR, MP, Electroencephalography, COVID-19, ECG, Growth, Thermoregulation, Computer, Blood pressure, Music, Headphones, Heart rate, Smartphone, Fast-moving consumer goods, Pet

The "Earphones and Headphones - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Earphones and Headphones - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Earphones, one of the segments analyzed in the report, is projected to grow at a 10.7% CAGR to reach US$22.3 Billion by the end of the analysis period.
  • This segment currently accounts for a 43.8% share of the global Earphones and Headphones market.
  • Headphones and earphones boast enhanced filtering for sound quality and are poised to benefit from ongoing efforts to further improve hearing quality for users.

Global Earphones and Headphones Market Report 2022-2026 - Rise of VR & AR-Based Training Across Industry Verticals Increases Demand for Headphones for Truly Immersive Experience

Retrieved on: 
Wednesday, January 19, 2022
Atmos, Dolby Atmos, CAGR, MP, Electroencephalography, COVID-19, ECG, Growth, Thermoregulation, Computer, Blood pressure, Music, Headphones, Heart rate, Smartphone, Fast-moving consumer goods, Pet

DUBLIN, Jan. 19, 2022 /PRNewswire/ -- The "Earphones and Headphones - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 19, 2022 /PRNewswire/ -- The "Earphones and Headphones - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Earphones, one of the segments analyzed in the report, is projected to grow at a 10.7% CAGR to reach US$22.3 Billion by the end of the analysis period.
  • This segment currently accounts for a 43.8% share of the global Earphones and Headphones market.
  • Headphones and earphones boast enhanced filtering for sound quality and are poised to benefit from ongoing efforts to further improve hearing quality for users.

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Retrieved on: 
Tuesday, January 11, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Alternative Medicine, Health, FDA, U.S. Securities and Exchange Commission, Forward-looking statement, Patient, Research, News, Psilocybin, Magnetic resonance imaging, COVID-19, Inc., Electroencephalography, NYSE American, NYSE, Safety, Institutional review board, Growth, Health Canada, Disease, Electrode, Â, Time, Psychedelic drug, View, Goal, Regulation of tobacco by the U.S. Food and Drug Administration, Company, Head, Lists of diseases, Therapy, Food and Drug Administration, Food, Engineering, Investigational New Drug, NEO, EDGAR, Risk, Pharmaceutical industry, Medical imaging, Kernel Flow, Cybin, KERNEL FLOW, CYBIN

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that an Institutional Review Board (IRB) has approved a Company-sponsored feasibility study using Kernels quantitative neuroimaging technology, Kernel Flow, to measure ketamines psychedelic effect on cerebral cortex hemodynamics.

Key Points: 
  • Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that an Institutional Review Board (IRB) has approved a Company-sponsored feasibility study using Kernels quantitative neuroimaging technology, Kernel Flow, to measure ketamines psychedelic effect on cerebral cortex hemodynamics.
  • By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting, said Doug Drysdale, Cybins Chief Executive Officer.
  • The study received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) authorization in October 2021 and is expected to begin enrollment in early 2022.
  • Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information.

Cerebral and Alto Neuroscience Enter into Strategic Collaboration to Launch First-Ever Decentralized Study in Precision Psychiatry

Retrieved on: 
Thursday, December 16, 2021
Data Management, Mental Health, Health, Technology, Software, Pharmaceutical, Biotechnology, FDA, Gaps, Sleep, History, Psychiatry, Clinical trial, Biology, PTSD, Brain, Biomarker, Genetics, EEG, Drug discovery, Cognition, Patient, Mental health, Electroencephalography, Multimedia, MBA, Lists of diseases, Twitter, Partnership, Trial of the century, Depression, Pharmaceutical industry, Medical imaging, Cerebral, Cerebral, Alto Neuroscience, CEREBRAL, ALTO NEUROSCIENCE

Cerebral , Inc. and Alto Neuroscience Inc. today announced a partnership to launch the first-ever decentralized clinical study in precision psychiatry, thereby accelerating the development and deployment of effective treatments in mental healthcare.

Key Points: 
  • Cerebral , Inc. and Alto Neuroscience Inc. today announced a partnership to launch the first-ever decentralized clinical study in precision psychiatry, thereby accelerating the development and deployment of effective treatments in mental healthcare.
  • Data from the first Phase 2 study within the collaboration is expected to read out by the end of 2022.
  • Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience added, The days of relying on trial-and-error for treating mental health conditions are over.
  • Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster.

Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

Retrieved on: 
Wednesday, October 27, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Research, Polysomnography, Electroencephalography, III, SZ, Lists of diseases, Magnetic resonance, Memory, Drug discovery, Mental disorder, Sodium- and chloride-dependent glycine transporter 1, Boehringer Ingelheim, University College London Hospitals NHS Foundation Trust, Corporate headquarters, Life, Medicine, Government budget balance, Cognition, Trial of the century, Biomarker, Work, Attention, Emotion, Schizophrenia, Psychiatry, Solution, EEG, MDD, Institute of Psychiatry, Psychology and Neuroscience, Institute, Boehringer, Central nervous system, Psychology, Department, Neuroimaging, Pharmaceutical industry

Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ).

Key Points: 
  • Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ).
  • We are delighted to collaborate with Kings IoPPN, a leading institute for research in psychiatry, said Dr Vikas Mohan Sharma, Head of Medicine CNS, Retinopathies & Emerging Areas at Boehringer Ingelheim.
  • This collaboration will advance our understanding to better assess cognition and those biomarkers linked to cognitive deterioration in people with major depressive disorder and schizophrenia.
  • We look forward to jointly creating opportunities to accelerate future clinical trials and the development of treatments for the many people impacted by psychiatric disorders.

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology

Retrieved on: 
Tuesday, October 26, 2021
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Safety, Magnetic resonance imaging, Head, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Goal, Electroencephalography, EDGAR, View, Psilocybin, NYSE, Food, Lists of diseases, Health Canada, U.S. Securities and Exchange Commission, Inc., Time, Brain, Forward-looking statement, Investigational New Drug, Company, Electrode, NEO, NYSE American, COVID-19, Growth, News, Acquisition, Therapy, Risk, Pharmaceutical industry, Medical imaging

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to proceed with the Companys sponsored feasibility study using Kernels Flow technology to measure ketamines psychedelic effect on cerebral cortex hemodynamics.

Key Points: 
  • Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to proceed with the Companys sponsored feasibility study using Kernels Flow technology to measure ketamines psychedelic effect on cerebral cortex hemodynamics.
  • With Kernel Flow, Cybin's researchers can start putting numbers and quantification to subjective states of mind, including altered ones.
  • As part of Cybins sponsorship of the feasibility study, the Company will retain an exclusive interest in any innovations that are discovered or developed through its independent analysis of the study findings.
  • If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

Nihon Kohden’s Late Takuo Aoyagi, PhD, Receives American Society of Anesthesiologists Honorary Member Award

Retrieved on: 
Monday, October 11, 2021
General Health, Health, Medical Devices, History, Life, Anesthesiology, American Society of Anesthesiologists, Electroencephalography, Industry, Society, Honorary, Medicine, Aoyagi, Patient, Research, Head, Ecosystem, Medical device

The Honorary Member Award celebrates a physician, scientist, or eligible member, who has attained outstanding eminence in anesthesiology or related fields.

Key Points: 
  • The Honorary Member Award celebrates a physician, scientist, or eligible member, who has attained outstanding eminence in anesthesiology or related fields.
  • Dr. Aoyagi dedicated his career to developing the essential technology thats used in patient monitoring and neurology devices worldwide.
  • This Nihon Kohden story begins in the late 1940s with a young Japanese researcher observing an experiment being performed on a small birds wings.
  • Nihon Kohden products are used in over 120 countries and is the largest supplier of electroencephalography products in the world.